Cosmos Health Inc. — fact timeline

Cosmos Health Inc. reported first quarter ended March 31, 2026 results: revenue $17.93 million, net income ($2.81 million).

“added at CosmoFarm, growing Sky Premium Life order activity across multiple markets, and expanded contract manufacturing agreements at Cana Laboratories. · Revenue was $17.93 million, an increase of 30.7% from $13.71 million in Q1 2025, reflecting strong sales momentum across all core divisions. ○ Adjusted revenue was $18.40 million, up 34.2% year-over-year,”

Cosmos Health Inc. reported the full year ended December 31, 2025 results: revenue $65.27 million, net income ($19.14 million), EPS ($0.63).

“through Decahedron in the United Kingdom, and the global expansion of proprietary brands, including Sky Premium Life and C-Scrub. Key Metric FY 2025 FY 2024 Change (in $) Revenue 65,271,815 54,426,402 +20 % Gross Profit 7,895,575 4,311,323 +83 % Gross Margin 12.10 % 7.92 % +418 basis points Adjusted EBITDA (3,361,385 ) (3,438,975 ) 2% improvement Adjusted Net Income”

Cosmos Health Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“December 11, 2025, Cosmos Health Inc. (the “Company”) received a non-compliance letter from Nasdaq for its failure to maintain a minimum bid price of $1.00 per share for thirty (30) consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2) (the “Listing Rule”). The Company has one hundred eighty (180) calendar days from December 11, 2025, to regain compliance by maintaining the closing bid price of the Company’s common stock of at least $1.00 per share for a minimum of ten (10) consecutive business days. In the event the Company cannot otherwise regain compliance with the Lis”

Cosmos Health Inc.: Approved amendment to Articles of Incorporation to increase authorized shares to 1.5B common and 300M blank-check preferred.

“the Amendment will become effective upon its filing with the Secretary of State of the State of Nevada”

Cosmos Health Inc. incurred convertible notes of $300,000,000 with an institutional investor at 9% per annum maturing twenty four (24) months after its respective issuance date.

“the Company agreed to issue and sell to the Purchaser a series of 9% original issue discount senior secured convertible promissory notes (each, a “ Note ” and collectively, the “ Notes ”) in the maximum aggregate principal amount of $300,000,000 (the “ Note Offering ”)”

Cosmos Health Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“May 6, 2025, Cosmos Health Inc. (the “Company”) announced that it has received a formal notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is eligible for an additional one hundred eighty (180) calendar day period, through November 3, 2025, to regain compliance with the Nasdaq’s minimum bid price requirement as one of the continued listing requirements set forth under Nasdaq Listing Rule 5550(a)(2). As previously disclosed, on November 6, 2024, the Company received a non-compliance letter from Nasdaq for its failure to maintain a minimum bid price of $1.00 per share”

Cosmos Health Inc. dismissed KPMG Certified Auditors S.A. as its auditor.

“On April 26, 2024, the Company dismissed KPMG as the Company’s independent registered accountant, effective immediately.”

Cosmos Health Inc. dismissed KPMG Certified Auditors S.A. as its auditor.

“1;) to report the dismissal of KPMG Certified Auditors S.A. (“KPMG”) as the Company’s independent registered public accounting firm, effective immediately, and related matters under Item 4.01 of Form 8-K 0001474167 2024-04-26 2024-04-26 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (AMENDMENT NO. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2024 Cosmos Health Inc. (Exact name of registrant as specified in its charter) Nevada 000-54436 27-0611758 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 141 West Jackson Blvd , Suite 4236 , Chicago , Illinois 60604 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code ( 312 ) 865-0026 N”

Cosmos Health Inc. dismissed KPMG Certified Auditors S.A. as its auditor.

“On April 26, 2024, Cosmos Health Inc. (the “Company”) dismissed KPMG Certified Auditors S.A., Athens, Greece, (“KPMG”) as the Company’s independent registered accountant, effective immediately.”

Cosmos Health Inc. entered into Rights Agreement with Globex Transfer, LLC (effective 2024-04-22).

“On April 22, 2024, Cosmos Health Inc. (the “Company”) entered into a Rights Agreement (the “Rights Agreement”), by and between the Company and Globex Transfer, LLC, as Rights Agent”

Cosmos Health Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 17, 2024, it received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that, because the Company has not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023 (the “Form 10-K”), the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. The Nasdaq letter has no immediate effect on the listing of the Company’s shares. As a non-compliant company, an indicator reflecti”

Cosmos Health Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 20, 2024, Cosmos Health Inc. (the “Company”) received a non-compliance letter from Nasdaq for its failure to maintain a minimum bid price of $1.00 per share for thirty (30) consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2). The Company has one hundred eighty (180) calendar days from March 20, 2024 to regain compliance by the closing bid price of the Company’s common stock being at least $1.00 per share for ten (10) consecutive business days. In the event the Company cannot otherwise regain compliance with the listing rule, it intends to effect a reverse stock sp”

Cosmos Health Inc. entered into Warrant Exchange Agreement with one holder of certain Company’s warrants (effective 2023-12-28).

“On December 28, 2023, Cosmos Health Inc. (the “Company”) entered into a warrant exchange agreement (the “Warrant Exchange Agreement”) with one holder of certain Company’s warrants issued on July 21, 2023 and December 21, 2022 (the “Existing Warrants”), pursuant to which the holder will exchange the Existing Warrants for new warrants (the “New Warrants”) to purchase up to an aggregate 4,874,126 shares of Common Stock”

Cosmos Health Inc. entered into Warrant Exchange Agreement with one holder of certain Company's warrants (effective 2023-12-28).

“On December 28, 2023, Cosmos Health Inc. (the “Company”) entered into a warrant exchange agreement (the “Warrant Exchange Agreement”) with one holder of certain Company’s warrants issued on July 21, 2023 and December 21, 2022 (the “Existing Warrants”), pursuant to which the holder will receive new warrants (the “New Warrants”) to purchase up to an aggregate 4,874,126 shares of Common Stock, par value $0.001 per share (the “New Warrant Shares”), equal to 200% of the 1,915,323 Warrant Shares and 521,740 Warrant Shares issuable pursuant to the exercise of the Existing Warrants, in consideration for exercising for cash any and all such Existing Warrants.”

Cosmos Health Inc. reported the third quarter and nine months ended September 30, 2023 results: revenue $12.8 million. Guidance reaffirmed.

“a business update and reported financial results for the third quarter and nine months ended September 30, 2023. Third Quarter 2023 Financial Highlights · Revenues increased to $12.8 million from $12.0 million in Q3 2022, largely due to increased sales attributable to the logistics distribution business, which expanded following the acquisition of the Bikas GP”

Cosmos Health Inc. received a nasdaq other notice regarding other (rules 5810(c)(4)).

“September 27, 2023, Cosmos Health Inc. (the “Company”) received a Letter of Reprimand from the Nasdaq Stock Market in accordance with Listing Rule 5810(c)(4). Nasdaq had previously determined that the Company had not obtained prior shareholder approval for the October 2022 best-efforts public offering involving the issuance of 20% or more of the outstanding shares at less than the minimum price. Because the offering consisted of Units of common stock, Series A Warrants and Series B Warrants it was necessary to allocate a value to the warrants which resulted in the Units being sold at a great”

Cosmos Health Inc. shareholders approved To authorize the Board of Directors to amend the Articles of Incorporation to effect a reverse stock split of the Company's outstanding common stock at their discretion at the 2023-09-18 meeting.

“4. To authorize the Board of Directors to amend the Articles of Incorporation to effect a reverse stock split of the Company’s outstanding common stock at their discretion: For Against Abstain % Votes Affirmative 4,766,157 113,059 486 97.67 %”

Cosmos Health Inc. shareholders approved To approve the Company's 2023 equity incentive plan at the 2023-09-18 meeting.

“3. To approve the Company’s 2023 equity incentive plan: For Against Abstain % Votes Affirmative 4,596,072 277,077 6,553 94.19 %”

Cosmos Health Inc. shareholders approved To ratify the October 2022 Public Offering at the 2023-09-18 meeting.

“2. To ratify the October 2022 Public Offering: For Against Abstain % Votes Affirmative 4,770,999 106,633 2,070 97.77 %”

Cosmos Health Inc. shareholders approved Election of Directors at the 2023-09-18 meeting.

“1. Election of Directors: Nomination For Withheld % Votes Affirmative 01 - Grigorios Siokas 4,606,832 272,870 94.41 % 02 - Demetrios G. Demetriades 4,867,713 11,989 99.75 % 03 - John J. Hoidas 4,872,529 7,173 99.85 % 04 - Dr. Anastasios Aslidis 4,808,836 70,866 98.55 % 05 - Dr. Manfred Ziegler 4,829,695 50,007 98.98 % 06 - Suhel Bhutawala 4,829,523 50,179 98.97 %”

Pavlos Ignatiades resigned as Chief Communications Officer at Cosmos Health Inc..

“On September 20, 2023, Pavlos Ignatiades, our Chief Communications Officer, resigned effective immediately.”

Cosmos Health Inc. reported H1 2023 results: revenue $24.71 million, net income $3.01 million.

“Revenues amounted to $12.36 million in Q2 2023 and $24.71 million in H1 2023”

Cosmos Health Inc. reported second quarter of 2023 results: revenue $12.36 million, net income $0.16 million.

“products, and operator of a telehealth platform, today reported its financial results for the second quarter of 2023. Q2 and H1 2023 Financial Highlights · Revenues amounted to $12.36 million in Q2 2023 and $24.71 million in H1 2023, a slight decline of 6.4% and 5.96%, respectively, from $13.21 million and $26.28 million in the corresponding periods in 2022, in part”

Cosmos Health Inc. engaged KPMG Certified Auditors as its auditor.

“On August 7, 2023, KPMG Certified Auditors, Athens, Greece, was appointed as the Company's independent registered public accounting firm upon recommendation by the Audit Committee of the Company's Board of Directors (the "Board") and the approval of the Board, to review the Company's Third Quarter Form 10-Q and audit the Company's consolidated financial statements as of and for the fiscal year ended December 31, 2023.”

Armanino LLP resigned as auditor of Cosmos Health Inc..

“☐ ITEM 4.01 CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT (a) Resignation of Previous Independent Registered Public Accounting Firm On August 1, 2023, Armanino LLP (the “Former Auditor”) advised Cosmos Health Inc.”

Cosmos Health Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2023-07-20).

“Pursuant to a Placement Agency Agreement dated July 20, 2023, the Company engaged A.G.P./Alliance Global Partners as sole Placement Agent in connection with the Offering.”

Cosmos Health Inc. entered into Securities Purchase Agreement with certain institutional investors and existing shareholders valued at approximately $5,250,000 (effective 2023-07-20).

“On July 20, 2023, Cosmos Health Inc. (“we,” “our,” “us,” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors and existing shareholders (the “Purchasers”), for a registered direct offering and a concurrent private placement.”

Cosmos Health Inc. completed an acquisition involving Pharmaceutical Laboratories CANA, S.A. for approximately $1.67 million (closed 2023-06-30).

“On June 30, 2023, Cosmos Health Inc. (the “Company”) completed the acquisition of one hundred (100%) percent of the equity of Pharmaceutical Laboratories CANA, S.A. (“Cana Holdings”). The Purchase Price for the shares was approximately $1.67 million consisting of €800,000 in cash and $800,000 in stock, based on an issuance price of $17.25 per share.”

Cosmos Health Inc. reported fiscal year ended December 31, 2022 results: revenue $50.3 million, net income $(13,830,371).

“devices, today provided a business update and reported financial results for the fiscal year ended December 31, 2022. Fiscal Year 2022 Financial Highlights · Revenues were $50.3 million versus $56.2 million in FY2021 with the decline being largely due to the high variation in FX differences between EUR and GBP to USD. When considered on a constant currency”

Cosmos Health Inc. entered into Secured Promissory Note with Cana Laboratories Holdings (Cyprus) Limited valued at 5,000,000 EUR (effective 2023-02-28).

“On February 28, 2023, Cosmos Health Inc. (the “Company”) was issued a five-year secured promissory note (the “Note”) in the principal amount of 4,100,000.00 EUR by Cana Laboratories Holdings (Cyprus) Limited, a corporation organized under the laws of the Republic of Cyprus (“Cana Holdings”).”

Pavlos Ignatiades was appointed as Chief Communications Officer (CCO) at Cosmos Health Inc..

“Nikos Bardakis will succeed Pavlos Ignatiades, who will assume the position of Chief Communications Officer (CCO).”

Nikos Bardakis was appointed as Chief Operating Officer (COO) at Cosmos Health Inc..

“On February 1, 2023, Cosmos Health Inc. (the 'Company') announced the appointment of Nikos Bardakis (54), who comes with over two decades of international branded pharmaceutical sector experience, as the Chief Operating Officer (COO).”

Cosmos Health Inc. entered into Securities Purchase Agreement with certain institutional investors valued at $32,525,680 (effective 2022-12-19).

“On December 19, 2022, Cosmos Health Inc. (“we,” “our,” “us,” or the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), for a registered direct offering and a concurrent private placement.”

Cosmos Health Inc.: Effected a 1-for-25 reverse stock split of common stock and changed company name from Cosmos Holdings to Cosmos Health (effective 2022-12-15).

“On the same day, the Company filed a Certificate of Amendment to the Company’s Articles of Incorporation with the Secretary of Nevada to effect the Reverse Stock Split (the “Amendment”) and the name change, which became effective at 12:07 P.M., Local Time, on December 15, 2022.”

Cosmos Health Inc. shareholders approved Authorize Board to amend Articles of Incorporation to effect a reverse stock split at the 2022-12-02 meeting.

“6. To authorize the Board of Directors to amend the Articles of Incorporation to effect a reverse stock split of the Company’s outstanding common stock at their discretion: For Against Abstain Broker Non-Vote % Votes Affirmative 9,601,860.07 241,339.00 4,567.00 -0- 98%”

Cosmos Health Inc. shareholders approved Approve amendment to Articles of Incorporation to change the company's name at the 2022-12-02 meeting.

“5. To approve the amendment to the Company’s Articles of Incorporation to the change the Company’s name: For Against Abstain Broker Non-Vote % Votes Affirmative 9,640,286.00 123,533.00 83,947.07 -0- 98%”

Cosmos Health Inc. shareholders approved Advisory vote to approve compensation of named executive officers (Say on Pay Vote) at the 2022-12-02 meeting.

“4. To cast a non-binding, advisory vote to approve the compensation of our named executive officers (“Say on Pay Vote”): For Against Abstain Broker Non-Vote % Votes Affirmative 9,417,734.07 125,845.00 112,004.00 192,183.00 98%”

Cosmos Health Inc. shareholders voted on Advisory vote on the frequency of say-on-pay votes at the 2022-12-02 meeting.

“3. To cast a non-binding, advisory vote on the frequency with which the Company’s shareholders shall have an advisory say on pay vote on the compensation of the Company’s named executive officers: Every Year Every 2 Years Every 3 Years Abstain Broker Non-Vote % Votes Affirmative 629,811.07 32,783.00 8,986,405.00 6,584.00 192,183.00 93%”

Cosmos Health Inc. shareholders approved To approve the Company's 2022 equity incentive plan at the 2022-12-02 meeting.

“2. To approve the Company’s equity incentive plan: For Against Abstain Broker Non-Vote % Votes Affirmative 9,425,609.07 143,935.00 86,039.00 192,183.00 98%”

Cosmos Health Inc. shareholders approved Election of Directors at the 2022-12-02 meeting.

“1. Election of Directors: Nomination For Withheld Broker Non-Votes % Votes Affirmative 01 - Grigorios Siokas 9,465,343.07 190,240.00 192,183.00 98% 02 - Demetrios G. Demetriades 9,451,581.00 204,002.07 192,183.00 98% 03 - John J. Hoidas 9,546,646.07 108,937.00 192,183.00 99% 04 - Dr. Anastasios Aslidis 9,533,573.00 122,010.07 192,183.00 99% 05 - Dr. Manfred Ziegler 9,547,184.07 108,399.00 192,183.00 99%”

Cosmos Health Inc. reported third quarter 2022 results: revenue $12.0M.

“· Revenues were $12.0M versus $13.6M in 3Q21.”

Cosmos Health Inc. received a nasdaq delisting notice notice regarding minimum bid price.

“Form 25-NSE with the SEC to remove the Company’s securities from listing and registration on the Nasdaq Stock Market. Although there is no assurance, we expect that the shareholder proposal at our scheduled December 2, 2022 Annual Shareholders Meeting, for which we have obtained a quorum, to provide the Board of Directors with the discretion to effect a reverse stock split, will enable us to regain compliance with Nasdaq’s minimum bid-price requirement for continued listing on the Nasdaq Capital Market.”

Cosmos Health Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5810(c)(3)(A)(ii)).

“November 10, 2022, Cosmos Holdings Inc. (the “Company”) received a non-compliance letter from the Nasdaq Stock Market for its failure to maintain a minimum closing bid price of $0.10 per share for ten (10) consecutive business days in accordance with Nasdaq Listing Rule 5810(c)(3)(A)(ii). Pursuant to a prior non-compliance letter from Nasdaq dated July 26, 2022, the Company had until January 23, 2023 to regain compliance by the closing bid price of the Company’s common stock being at least $1.00 per share for ten (10) consecutive trading days. The Staff has determined to suspend trading of the”

Anastasios Aslidis was appointed as Director at Cosmos Health Inc..

“On April 28, 2022, the Board appointed Dr. Anastasios Aslidis to the Board of Directors and as a member of the Board’s audit committee.”

Peter Goldstein resigned as Director at Cosmos Health Inc..

“Effective April 28, 2022, Peter Goldstein resigned from the Board of Directors (the “Board”) of Cosmos Holdings Inc. (the “Company”) and from the Board’s audit committee.”